Table 4.
Baseline characteristics: no statistical differences between eplerenone and control group
| All | Eplerenone group | Control group | |
|---|---|---|---|
| Number, n | 84 | 42 | 42 |
| Age at inclusion, years (SD) | 39.5 (±13.1) | 40.2 (±13.0) | 38.8 (±13.4) |
| Male sex, n (%) | 37 (44) | 18 (43) | 19 (45) |
| Body mass index, kg/m2 (SD) | 25.7 (±4.8) | 26.5 (±5.6) | 24.9 (±3.6) |
| Systolic blood pressure, mm Hg (SD) | 124 (±16) | 128 (±17) | 121 (±13) |
| Diastolic blood pressure, mm Hg (SD) | 74 (±11) | 75 (±10) | 74 (±11) |
| ECG repolarisation abnormalities, n (%) | 18 (21) | 13 (31) | 5 (12) |
| VPC, n (range) | 8 (0–1861) | 8 (0–1498) | 12 (0–1861) |
| LVEDV, ml (SD) | 157 (±28) | 160 (±23) | 154 (±34) |
| LVEF, % (SD) | 60 (±0.04) | 60 (±0.04) | 59 (±0.05) |
| LV-LGE, n (%) | 14 (18) | 9 (22) | 5 (13) |
| RVEDV, ml (SD) | 178 (±34) | 179 (±27) | 176 (±42) |
| RVEF, % (SD) | 52 (±0.04) | 52 (±0.04) | 51 (±0.04) |
SD standard deviation, ECG electrocardiogram, VPC ventricular premature complexes, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LV-LGE left ventricular late gadolinium enhancement, RVEDV right ventricular end-diastolic volume, RVEF right ventricular ejection fraction